Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...

The drug's safety profile was consistent with that found in prior studies, with no new safety signals identified.

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD- (L)1xVEGF world, Akeso ...

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...

Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other anti-cancer antibodies.

Market volatility has led to compelling dividend opportunities, and Merck and Schlumberger offer great value at low PE ratios ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...

MerckMRK reported its first-quarter 2025 results last week, beating estimates for both earnings and sales. Adjusted earnings ...

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 ...